Martín-Aguilar L, Lleixà C, Pascual-Goñi E, Caballero-Ávila M, Martínez-Martínez L, Díaz-Manera J, Rojas-García R, Cortés-Vicente E, Turon-Sans J, de Luna N, Suárez-Calvet X, Gallardo E, Rajabally Y, Scotton S, Jacobs BC, Baars A, Cortese A, Vegezzi E, Höftberger R, Zimprich F, Roesler C, Nobile-Orazio E, Liberatore G, Hiew FL, Martínez-Piñeiro A, Carvajal A, Piñar-Morales R, Usón-Martín M, Albertí O, López-Pérez MÁ, Márquez F, Pardo-Fernández J, Muñoz-Delgado L, Cabrera-Serrano M, Ortiz N, Bartolomé M, Duman Ö, Bril V, Segura-Chávez D, Pitarokoili K, Steen C, Illa I, Querol L. Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. Neurology-Neuroimmunology & Neuroinflammation. 2022; 9(1)DOI:10.1212/NXI.0000000000001098. PMID:34728497. IF:8.800(Q1/1D).

Caballero-Ávila M., Álvarez-Velasco R., Moga E., Rojas-Garcia R., Turon-Sans J., Querol L., Olivé M., Reyes-Leiva D., Illa I., Gallardo E., Cortés-Vicente E.. Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia. NEUROMUSCULAR DISORDERS. 2022; 32(8)DOI:10.1016/j.nmd.2022.06.006. PMID:35811274. IF:2.800(Q3/6D).

Ingelfinger F., Sparano C., Bamert D., Reyes-Leiva D., Sethi A., Rindlisbacher L., Zwicky P., Kreutmair S., Widmer C.C., Mundt S., Cortés-Vicente E., Tugues S., Becher B., Schreiner B.. Azathioprine therapy induces selective NK cell depletion and IFN-? deficiency predisposing to herpesvirus reactivation. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2022; 151(1)DOI:10.1016/j.jaci.2022.09.010. PMID:36122787. IF:14.200(Q1/1D).

Bolano-Diaz, C, Diaz-Manera, J. Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management. Therapeutics and Clinical Risk Management. 2022; 18DOI:10.2147/TCRM.S334232. PMID:36536827. IF:2.800(Q3/6D).

Querol L.A., Hartung H.-P., Lewis R.A., van Doorn P.A., Hammond T.R., Atassi N., Alonso-Alonso M., Dalakas M.C.. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics. 2022; 19(3)DOI:10.1007/s13311-022-01221-y. PMID:35378684. IF:5.700(Q1/2D).

Mayhew A.G., James M.K., Moore U., Sutherland H., Jacobs M., Feng J., Lowes L.P., Alfano L.N., Muni Lofra R., Rufibach L.E., Rose K., Duong T., Bello L., Pedrosa-Hernández I., Holsten S., Sakamoto C., Canal A., Sánchez-Aguilera Práxedes N., Thiele S., Siener C., Vandevelde B., DeWolf B., Maron E., Gordish-Dressman H., Hilsden H., Guglieri M., Hogrel J.-Y., Blamire A.M., Carlier P.G., Spuler S., Day J.W., Jones K.J., Bharucha-Goebel D.X., Salort-Campana E., Pestronk A., Walter M.C., Paradas C., Stojkovic T., Mori-Yoshimura M., Bravver E., Díaz-Manera J., Pegoraro E., Mendell J.R., Straub V.. Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis Approach. Frontiers in Neurology. 2022; 13DOI:10.3389/fneur.2022.828525. PMID:35359643. IF:3.400(Q2/5D).

Doets A.Y., Lingsma H.F., Walgaard C., Islam B., Papri N., Davidson A., Yamagishi Y., Kusunoki S., Dimachkie M.M., Waheed W., Kolb N., Islam Z., Mohammad Q.D., Harbo T., Sindrup S.H., Chavada G., Willison H.J., Casasnovas C., Bateman K., Miller J.A.L., van den Berg B., Verboon C., Roodbol J., Leonhard S.E., Benedetti L., Kuwabara S., van den Bergh P., Monges S., Marfia G.A., Shahrizaila N., Galassi G., Péréon Y., Bürmann J., Kuitwaard K., Kleyweg R.P., Marchesoni C., Sedano Tous M.J., Querol L., Illa I., Wang Y., Nobile-Orazio E., Rinaldi S., Schenone A., Pardo J., Vermeij F.H., Lehmann H.C., Granit V., Cavaletti G., Gutiérrez-Gutiérrez G., Barroso F.A., Visser L.H., Katzberg H.D., Dardiotis E., Attarian S., van der Kooi A.J., Eftimov F., Wirtz P.W., Samijn J.P.A., Jacobus Gilhuis H., Hadden R.D.M., Holt J.K.L., Sheikh K.A., Karafiath S., Vytopil M., Antonini G., Feasby T.E., Faber C.G., Gijsbers C.J., Busby M., Roberts R.C., Silvestri N.J., Fazio R., van Dijk G.W., Garssen M.P.J., Straathof C.S.M., Gorson K.C., Jacobs B.C.. Predicting Outcome in Guillain-Barré Syndrome International Validation of the Modified Erasmus GBS Outcome Score. NEUROLOGY. 2022; 98(5)DOI:10.1212/WNL.0000000000013139. PMID:34937789. IF:9.900(Q1/1D).

Aretouli, E, Chondrogiorgi, M, Dede, O, Koutsonida, M, Lafi, C, Konstantinopoulou, E, Kulisevsky, J, Kosmidis, MH, Konitsiotis, S. The Parkinson's Disease-Cognitive Rating Scale: Greek Normative Data, Clinical Utility and Cultural Considerations. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY. 2022; 35(5)DOI:10.1177/08919887211049110. PMID:34663111. IF:2.600(Q3/7D).

Sampedro, F, Kulisevsky, J. Intracortical surface-based MR diffusivity to investigate neurologic and psychiatric disorders: a review. JOURNAL OF NEUROIMAGING. 2022; 32(1)DOI:10.1111/jon.12930. PMID:34506674. IF:2.400(Q3/6D).

Ferreira, JJ, Rodrigues, FB, Duarte, GS, Mestre, TA, Bachoud-Levi, AC, Bentivoglio, AR, Burgunder, JM, Cardoso, F, Claassen, DO, Landwehrmeyer, GB, Kulisevsky, J, Nirenberg, MJ, Rosser, A, Roth, J, Seppi, K, Slawek, J, Furr-Stimming, E, Tabrizi, SJ, Walker, FO, Vandenberghe, W, Costa, J, Sampaio, C. An MDS Evidence-Based Review on Treatments for Huntington's Disease. MOVEMENT DISORDERS. 2022; 37(1)DOI:10.1002/mds.28855. PMID:34842303. IF:8.600(Q1/1D).

Garcia, DS, Roca, LG, Fonticoba, TD, Bartolome, CC, Rios, LN, Canfield, H, Gonzalez, JMP, Miro, CM, Jesus, S, Aguilar, M, Pastor, P, Planellas, L, Cosgaya, M, Caldentey, JG, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Rivera, MAA, Mayordomo, VG, Nogueira, V, Puente, V, Garcia-Soto, JD, Borrue, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Padilla, FC, Castrillo, JCM, Alonso, PS, Losada, MGA, Ariztegui, NL, Gaston, I, Kulisevsky, J, Estrada, MB, Seijo, M, Martinez, JR, Valero, C, Kurtis, M, de Fabregues, O, Ardura, JG, Redondo, RA, Ordas, C, Diaz, LML, McAfee, D, Martinez-Martin, P, Mir, P. Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. Journal of Parkinsons Disease. 2022; 12(1)DOI:10.3233/JPD-212868. PMID:34602501. IF:5.200(Q1/3D).

Garcia, DS, Sauco, MA, Calopa, M, Carrillo, F, Sevilla, FE, Freire, E, Ramos, RG, Kulisevsky, J, Esteban, JCG, Legarda, I, Luquin, MRI, Castrillo, JCM, Martinez-Martin, P, Martinez-Torres, I, Mir, P, Ignacio, AS. MNCD: A New Tool for Classifying Parkinson's Disease in Daily Clinical Practice. Diagnostics. 2022; 12(1)DOI:10.3390/diagnostics12010055. PMID:35054222. IF:3.600(Q2/4D).

Santos García D, Canfield H, de Deus Fonticoba T, Cores Bartolomé C, Naya Ríos L, García Roca L, Martínez Miró C, Jesús S, Aguilar M, Pastor P, Cosgaya M, García Caldentey J, Caballol N, Legarda I, Hernández Vara J, Cabo I, López Manzanares L, González Aramburu I, Ávila Rivera MA, Gómez Mayordomo V, Nogueira V, Puente V, Dotor J, Borrué C, Solano Vila B, Álvarez Sauco M, Vela L, Escalante S, Cubo E, Carrillo Padilla F, Martínez Castrillo JC, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Kulisevsky J, Blázquez Estrada M, Seijo M, Rúiz Martínez J, Valero C, Kurtis M, de Fábregues O, González Ardura J, Alonso Redondo R, Ordás C, López Díaz LM, McAfee D, Martinez-Martin P, Mir P, COPPADIS Study Group. Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Parkinsons Disease. 2022; 12(3)DOI:10.3233/JPD-213004. PMID:34957949. IF:5.200(Q1/3D).

Sampedro, F, Martinez-Horta, S, Marin-Lahoz, J, Pagonabarraga, J, Kulisevsky, J. Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson's Disease. Journal of Parkinsons Disease. 2022; 12(5)DOI:10.3233/JPD-223223. PMID:35491803. IF:5.200(Q1/3D).

Abbruzzese, G, Kulisevsky, J, Bergmans, B, Gomez-Esteban, JC, Kagi, G, Raw, J, Stefani, A, Warnecke, T, Jost, WH. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial (vol 11, pg 187, 2021). Journal of Parkinsons Disease. 2022; 12(1)DOI:10.3233/JPD-219007. PMID:34275911. IF:5.200(Q1/3D).

Bach-Morrow L., Boccalatte F., DeRosa A., Devos D., Garcia-Sanchez C., Inglese M., Droby A.. Functional changes in prefrontal cortex following frequency-specific training. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-24088-7. PMID:36434008. IF:4.600(Q2/4D).

Pou M.A., Orfila F., Pagonabarraga J., Ferrer-Moret S., Corominas H., Diaz-Torne C.. Le risque de maladie de Parkinson dans une population méditerranéenne de patients goutteux : étude cas-témoins. Revue Du Rhumatisme (edition Francaise). 2022; 89(6)DOI:10.1016/j.rhum.2022.09.019. PMID:. IF:(Q/D).

Kulisevsky J.. Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert. REVISTA DE NEUROLOGIA. 2022; 75(s04)DOI:10.33588/rn.75s04.2022217. PMID:36342310. IF:1.200(Q4/10D).

Rodríguez-Jorge F., Beltrán-Corbellini Á., Chico-García J.L., Parra-Díaz P., Baena-Álvarez B., Pagonabarraga J., Pérez-Torre P., Pareés I., López-Sendón J.L., Martínez-Castrillo J.C., Alonso-Cánovas A.. Efficacy and safety of high doses of safinamide in advanced Parkinson disease. PARKINSONISM & RELATED DISORDERS. 2022; 97DOI:10.1016/j.parkreldis.2022.03.010. PMID:35344893. IF:(Q/D).

Roch, G, Batalle, G, Bai, X, Pouso-Vazquez, E, Rodriguez, L, Pol, O. The Beneficial Effects of Heme Oxygenase 1 and Hydrogen Sulfide Activation in the Management of Neuropathic Pain, Anxiety- and Depressive-like Effects of Paclitaxel in Mice. Antioxidants. 2022; 11(1)DOI:10.3390/antiox11010122. PMID:35052626. IF:7.000(Q1/1D).